Last reviewed · How we verify
NCT00082550
Serotonin Transporters in Obsessive-Compulsive-Related Disorders
trial in Obsessive-Compulsive Disorder in 30 participants. Completed in 9 April 2007.
Quick facts
| Lead sponsor | National Institute of Mental Health (NIMH) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 10 May 2004 |
| Estimated completion | 9 April 2007 |
| Sites | 1 location across United States |
Conditions studied
- Obsessive-Compulsive Disorder — all drugs for Obsessive-Compulsive Disorder →
Sponsor
National Institute of Mental Health (NIMH)
Who can join
Adults 18 to 65, any sex, with Obsessive-Compulsive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will compare serotonin transporters in patients with obsessive-compulsive disorder (OCD) and healthy volunteers in order to better understand the role of serotonin in OCD. Serotonin is a chemical in the brain that transmits nerve impulses. The serotonin transporter (SERT) is a protein that regulates serotonin levels in the brain. Normal, healthy volunteers and patients with OCD between 18 and 50 years of age and in overall good health may be eligible for this study. Candidates are screened with a medical history, physical examination, blood and urine tests, and a psychological interview and tests related to OCD symptoms. Participants undergo the following tests: * Positron emission tomography (PET) scanning: For this test, subjects lie on the scanner bed, wearing special masks that are fitted to their heads and attached to the beds to help keep their heads still during the procedure. An 8-minute "transmission" scan is done to provide measures of the brain that will help calculate information obtained from subsequent scans. Then, a radioactive tracer is injected into a catheter (plastic tube) placed in the arm. The scan produces images of the serotonin transporters in the brain. Pictures are taken for about 2 hours, while the subject lies still on the scanner bed. * Magnetic resonance imaging (MRI) scanning: An MRI scan of the brain is done within 1 year of the PET scan-that is, up to 1 year before or 1 year after the PET scan. MRI uses a magnetic field and radio waves to produce images of body tissues and organs. For this procedure, the patient lies on a table that is moved into the scanner (a narrow cylinder), wearing earplugs to muffle loud knocking and thumping sounds that occur during the scanning process. The procedure lasts about 1 hour, during which the patient will be asked to lie still for up to a few minutes at a time. * Genotyping: Subjects provide a blood sample (4 tablespoons) for DNA testing to look for genes or gene regions that may contribute to serotonin activity. This may lead to a better understanding of the genetic underpinnings of the serotonin system that influence mood, movement, and addiction.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00082550
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obsessive-Compulsive Disorder
Currently open trials in the same condition.
- NCT06575075 — Pilot Study of RR-HNK in OCD · Phase 1, PHASE2 · recruiting
- NCT05783817 — MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) · Phase 2 · recruiting
- NCT07065669 — Treating Adolescent Obsessive Compulsive Disorder With Transcranial Magnetic Stimulation · NA · recruiting
- NCT06376734 — Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness · Phase 2 · recruiting
- NCT07000812 — EEG Evaluation of CBT for Obsessive-Compulsive Disorder · NA · active not recruiting
Other National Institute of Mental Health (NIMH) trials
Trials by the same sponsor.
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT05652465 — Transcranial Magnetic Stimulation for Youth With Treatment-Resistant Major Depressive Disorder · Phase 2 · suspended
- NCT07027839 — Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B) · Phase 1 · recruiting
- NCT06920628 — PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 In · Phase 1 · recruiting
- NCT06874205 — Assessment of 11C-JMJ-129 for Imaging PDE4D in Brain and Whole Body of Healthy Volunteers · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00082550 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute of Mental Health (NIMH)
- Last refreshed: 2 July 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00082550.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing